Resolving the dilemma of managing NSCLC patients with PD -L1 TPS ≥ 50%

March 18, 2022Playtime: 30:03

This site is intended for healthcare professionals only.

The content on this page is for updated scientific information exchange. MSD does not encourage any off-label prescription. Please prescribe the drug or medicine based on your country’s prescribing information.

For more information about Pembrolizumab, please visit our M-Connect portal